Peptidases and proteases are key targets for the pharmaceutical industry and inhibitors of these enzymes represent an extremely important class of therapeutics for the treatment of diseases associated with their uncontrolled activity. We will exploit our new approach to drug design to synthesise potent inhibitors of ACE2 - a recently discovered enzyme involved in cardiovascular function. This project has the potential to significantly impact on the field of drug design by providing a new avenue to accelerating the identification and development of lead compounds to give highly potent and stable drug candidates.
|Effective start/end date||1/01/05 → 31/12/07|
- Australian Research Council (ARC): AUD410,000.00
- Australian Research Council (ARC)